АДАМСОН Питер (GB),ШИМА Дэвид (GB),НГ Инь Шань Эрик (GB)
申请号：
RU2014126070
公开号：
RU2014126070A
申请日:
2012.11.30
申请国别(地区):
RU
年份:
2016
代理人:
摘要：
1. A method for the treatment and / or prevention of ocular disorders or diseases associated with neovascularization in a subject, comprising identifying a subject suffering from, or at risk of developing the eye disease or disorder associated with neovascularization, and administering to a subject in need thereof, a pharmaceutical composition comprising means for inhibiting the activity and / or expression CCR3.2 protein. A method according to Claim. 1, wherein the ophthalmic disease or disorder is a neovascular VDM.3. The method of treatment and / or prevention of ocular disorders or diseases associated with hyperpermeability of choroidal vessels in a subject, comprising identifying a subject suffering from, or at risk of developing a neovascular GMR or disorder associated with increased permeability of choroidal vessels, and administering to a subject in need Thus, a pharmaceutical composition comprising an agent for inhibiting activity and / or expression CCR3.4 protein. A method according to Claim. 1, wherein the ophthalmic disease or disorder is dry or geographic atrophic VDM.5. The method of treatment and / or prevention of SFH in a subject suffering from, or at risk of developing GMR comprising administering to the subject a pharmaceutical composition comprising an agent inhibiting activity and / or expression CCR3.6 protein. The method of claim. 5, wherein the inhibition of CCR3 protein reduces or eliminates VDM.7 symptom. The method of treatment and / or prevention of SFH in a subject suffering from, or at risk of developing GMR comprising administering to the subject a pharmaceutical composition comprising an agent inhibiting activity and / or1. Способ лечения и/или предотвращения глазного нарушения или заболевания, связанного с неоваскуляризацией, у субъекта, включающий выявление субъекта, страдающего от, или имеющего риск развития глазного заболевания или нарушения, связанного с неоваскуляризацией, и введение субъекту, нуждающемуся в этом, фармацевтичес
